62.06
price up icon0.05%   0.03
after-market アフターアワーズ: 62.00 -0.06 -0.10%
loading
前日終値:
$62.03
開ける:
$61.83
24時間の取引高:
1.21M
Relative Volume:
0.76
時価総額:
$11.25B
収益:
$2.75B
当期純損益:
$322.29M
株価収益率:
37.16
EPS:
1.67
ネットキャッシュフロー:
$300.88M
1週間 パフォーマンス:
-1.46%
1か月 パフォーマンス:
+2.99%
6か月 パフォーマンス:
-6.03%
1年 パフォーマンス:
-24.72%
1日の値動き範囲:
Value
$61.56
$62.83
1週間の範囲:
Value
$60.92
$65.40
52週間の値動き範囲:
Value
$52.93
$94.85

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1150)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,040
Name
Twitter
Name
次回の収益日
2024-10-29
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

BMRN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
62.06 11.25B 2.75B 322.29M 300.88M 1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.19 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
603.58 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.65 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
273.55 32.98B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
254.16 26.92B 3.81B -644.79M -669.77M -6.24

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
02:01 AM

10 Analysts Assess Biomarin Pharmaceutical: What You Need To Know - Benzinga

02:01 AM
pulisher
09:50 AM

Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance

09:50 AM
pulisher
May 04, 2025

BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN

May 04, 2025
pulisher
May 03, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025
pulisher
May 02, 2025

Biomarin Pharmaceutical (BMRN) Price Target Lowered by Citigroup - GuruFocus

May 02, 2025
pulisher
May 02, 2025

BioMarin Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks

May 02, 2025
pulisher
May 02, 2025

Cantor maintains BioMarin stock overweight with $90 target By Investing.com - Investing.com South Africa

May 02, 2025
pulisher
May 02, 2025

BioMarin's First-Quarter Earnings & Sales Beat Estimates - TradingView

May 02, 2025
pulisher
May 02, 2025

BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView

May 02, 2025
pulisher
May 02, 2025

Cantor maintains BioMarin stock overweight with $90 target - Investing.com

May 02, 2025
pulisher
May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025
pulisher
May 02, 2025

BioMarin’s Strong Q1 2025 Performance and Growth Outlook - TipRanks

May 02, 2025
pulisher
May 01, 2025

BioMarin Pharmaceutical Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 01, 2025
pulisher
May 01, 2025

BioMarin (BMRN) Reports Strong Q1 2025 Growth and Strategic Adva - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Biomarin Pharma earnings beat by $0.43, revenue topped estimates - Investing.com India

May 01, 2025
pulisher
May 01, 2025

BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: BioMarin beats Q1 2025 forecasts, stock rises after hours - Investing.com

May 01, 2025
pulisher
May 01, 2025

BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates - Nasdaq

May 01, 2025
pulisher
May 01, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

BMRN Q1 Revenue Surpasses Expectations with Strong Product Deman - GuruFocus

May 01, 2025
pulisher
May 01, 2025

BioMarin: Q1 Earnings Snapshot - News-Times

May 01, 2025
pulisher
May 01, 2025

BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Rise - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

BioMarin Pharmaceutical Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BMRN) - Seeking Alpha

May 01, 2025
pulisher
May 01, 2025

Biomarin Pharmaceutical Inc. Q1 Profit Increases, Beats Estimates - Nasdaq

May 01, 2025
pulisher
May 01, 2025

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PR Newswire

May 01, 2025
pulisher
May 01, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

May 01, 2025
pulisher
Apr 29, 2025

BioMarin Pharmaceutical Inc expected to post earnings of 71 cents a shareEarnings Preview - TradingView

Apr 29, 2025
pulisher
Apr 29, 2025

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey

Apr 29, 2025
pulisher
Apr 29, 2025

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings - Barchart.com

Apr 29, 2025
pulisher
Apr 27, 2025

Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment? - simplywall.st

Apr 27, 2025
pulisher
Apr 24, 2025

20 Takeover Rumors Hedge Funds Are Buying - Insider Monkey

Apr 24, 2025
pulisher
Apr 23, 2025

BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo

Apr 23, 2025
pulisher
Apr 23, 2025

Implied Volatility Surging for BioMarin Stock Options - Yahoo Finance

Apr 23, 2025
pulisher
Apr 21, 2025

Oppenheimer maintains BioMarin stock Outperform with $98 target By Investing.com - Investing.com Nigeria

Apr 21, 2025
pulisher
Apr 21, 2025

Oppenheimer maintains BioMarin stock Outperform with $98 target - Investing.com

Apr 21, 2025
pulisher
Apr 21, 2025

Joshua Grass, John Kelly, and Lauren Daniel Join 5AM Ventures - GlobeNewswire Inc.

Apr 21, 2025
pulisher
Apr 18, 2025

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance

Apr 18, 2025
pulisher
Apr 17, 2025

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - Longview News-Journal

Apr 17, 2025
pulisher
Apr 17, 2025

BioMarin Earnings Preview: New CEO Alexander Hardy to Reveal First Quarter Strategy Shift - Stock Titan

Apr 17, 2025
pulisher
Apr 17, 2025

Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com

Apr 17, 2025
pulisher
Apr 16, 2025

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction - Benzinga

Apr 16, 2025
pulisher
Apr 16, 2025

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo

Apr 16, 2025
pulisher
Apr 15, 2025

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals

Apr 15, 2025
pulisher
Apr 15, 2025

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com

Apr 15, 2025
pulisher
Apr 10, 2025

Quality Management Process LeadSan RafaelBioMarin Pharmaceutical - Ladders

Apr 10, 2025
pulisher
Apr 10, 2025

Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Astronics and Boston Beer have been highlighted as Zacks Bull and Bear of the Day - TradingView

Apr 10, 2025
pulisher
Apr 09, 2025

Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On - Yahoo Finance

Apr 09, 2025

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
大文字化:     |  ボリューム (24 時間):